(Q40754856)

23 September 2017

title

Haemodynamic effects of recombinant interleukin-2 administered by constant infusion (English)

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90426-E

22 November 2022

1 reference

adoptive immunotherapy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1782070

22 November 2022

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90426-E

22 November 2022

author name string

J. S. Groeger

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1782070

22 November 2022

D. Bajorin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1782070

22 November 2022

B. Reichman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1782070

22 November 2022

I. Kopec

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1782070

22 November 2022

O. Atiq

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1782070

22 November 2022

M. K. Pierri

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1782070

22 November 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1782070

22 November 2022

publication date

1 January 1991

1 reference

full work available at URL

23 September 2017

https://api.elsevier.com/content/article/PII:027753799190426E?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90426-E

https://api.elsevier.com/content/article/PII:027753799190426E?httpAccept=text/plain

22 November 2022

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90426-E

European Journal of Cancer

22 November 2022

published in

1 reference

23 September 2017

volume

27

1 reference

23 September 2017

issue

12

1 reference

23 September 2017

page(s)

1613-1616

1 reference

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

23 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90426-E

Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial

22 November 2022

2

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90426-E

A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma

22 November 2022

3

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90426-E

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

22 November 2022

4

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90426-E

Cardiorespiratory effects of immunotherapy with interleukin-2.

22 November 2022

5

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90426-E

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines

22 November 2022

6

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90426-E

The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells

22 November 2022

7

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90426-E

Cardiovascular consequences of recombinant DNA technology: interleukin-2.

22 November 2022

8

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90426-E

Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock.

22 November 2022

9

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90426-E

Myocardial toxic effects during recombinant interleukin-2 therapy

22 November 2022

10

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90426-E

Pulmonary edema as a complication of interleukin-2 therapy

22 November 2022

11

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90426-E

Renal, volume, and hormonal changes during therapeutic administration of recombinant interleukin-2 in man.

22 November 2022

12

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90426-E

Severe myocarditis following high-dose interleukin-2 administration

22 November 2022

13

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90426-E

Continuous infusion recombinant interleukin-2 (rIL-2) in adoptive cellular therapy of renal carcinoma and other malignancies

22 November 2022

15

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90426-E

Recombinant interleukin-2 by continuous infusion and adoptive transfer of recombinant interleukin-2-activated cells in patients with advanced cancer

22 November 2022

16

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90426-E

A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions

22 November 2022

17

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90426-E

Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin

22 November 2022

18

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90426-E

The cellular immunotherapy of cancer: current and potential uses of interleukin-2.

22 November 2022

19

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90426-E

Immunotherapy with interleukin-2 by constant infusion with and without adoptive cell transfer and with weekly doxorubicin

22 November 2022

20

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90426-E

A phase I-II study of high-dose recombinant human interleukin-2 in disseminated renal-cell carcinoma.

22 November 2022

21

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90426-E

22 November 2022

Identifiers

1 reference

23 September 2017

1 reference